We offer a comprehensive repertoire of cell biology based methods & models to delineate the molecular action of NCEs or novel formulations. Our assay development team can customize a range of in vitro, ex vivo and in vivo cell based models to determine the key cellular pathways determining the pharmacology of the lead molecules. The methodologies are designed to evaluate NCEs, Phytochemicals, or differentiated formulations. These mechanistic studies may be useful for selection of pharmacodynamic endpoints One or more of the following strategies may be undertaken to profile the molecule under investigation
Our preclinical In Vivo research platform are currently focused in the therapeutic areas of Oncology, Metabolic Disease, Inflammation, Hair Biology, Derma Pathology, Fertility, Gastrointestinal
A technically experienced team of scientists at DRF carry out in vitro ADME and in vivo Pharmacokinetic/ Toxicokinetics along with a well supported bioanalytical group to expedite the discovery process for the sponsor. The services offered include -
Toxicology Department of Dabur Research Foundation (DRF) has several years of experience and expertise to design and conduct toxicity studies with various route of administration viz., oral, dermal, Intravenous, subcutaneous, intraperitoneal, intramuscular etc. such as for Pharma, BioPharma, Agrochemicals, Specialty Chemicals in accordance with International Guidelines viz., ICH, EMEA, WHO, FDA, OECD, EU and OPPTS and National guidelines such as Schedule Y, CIB and AYUSH (CCRAS) and the studies are conducted in compliance with Good laboratory practices (GLP ).
The pathology laboratory has two functional areas i.e. histopathology and clinical pathology. The histopathology section performs the necropsy, tissue weighing and preservation, tissue processing and pathologist evaluation whereas clinical pathology carries out hematology, clinical chemistry and, coagulation and urine analysis which is mandatory in general toxicity evaluation.
DRF offers an array of Efficacy models focused toward early development of STEM Cell derived product .
The efficacy model includes:-